News

The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.

We were delighted to welcome CEO National Resilience Inc. Rahul Singhvi who visited our labs and office space.

Mark Kotter talks about the benefits of human cells for researchers, and how they can shape the future of drug development.

Leading experts across academia and industry share their thoughts into the challenges of in vitro cell models.

bit.bio CEO Dr Mark Kotter interviewed by Fiona Mischel on the Built with Biology Podcast.

They ask about reprogramming cells and how the company is aiming to develop cell therapies.

The article offers 6 tips for successful pharma startups.

This case study delves into the company story, technology and vision.